ER+HER2– grade III cancers experience higher pCR rates with neoadjuvant chemotherapy with and without IO; however, histologic grade seems to be a suboptimal criterion to select patients for IO therapy (24% pCR rate in KEYNOTE-756 and 45% pCR in I-SPY2). This evidence concerns the gene ERBB2 and cancer.